Timing of iodine-123 scintigraphy following use of recombinant human thyrotropin in differentiated thyroid carcinoma

Clinical Nuclear Medicine

Volumn 32, Issue 5, 2007, Pages 375-377

  Yan, Warren ^a   Roach, Paul J ^a   Bautovich, George J ^a   Learoyd, Diana L ^a   Robinson, Bruce G ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Differentiated thyroid carcinoma; Iodine 123 scintigraphy; Recombinant human thyrotropin (rhTSH thyrogen)

Indexed keywords

IODINE 123; RADIOPHARMACEUTICAL AGENT; RECOMBINANT HUMAN THYROTROPIN I 123; RECOMBINANT THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST FEEDING; CASE REPORT; DRUG UPTAKE; FEMALE; HUMAN; POSTOPERATIVE PERIOD; THYROID CARCINOMA; THYROID FUNCTION; THYROID SCINTISCANNING; THYROIDECTOMY; TREATMENT INDICATION;

ADULT; BREAST FEEDING; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; RADIONUCLIDE IMAGING; RECOMBINANT PROTEINS; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN; TIME FACTORS;

EID: 34247481306     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000259616.75495.b8     Document Type: Article

References (8)

1. Brzozowska M, Roach P. Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer: a case series. Clin Nucl Med. 2006;31:683-687.
2. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med. 2001;26:6-9.
3. Anderson GS, Fish S, Nakhoda K, Zzhuang H, Alavi A, Mandel S. Comparison of I-123 and I-131 for whole body imaging after stimulation by recombinant human thyrotropin. Clin Nuc Med. 2003;28:93-96.
4. Alzahrani AS, Bakheet S, Al Mandil M, et al. I123 isotope as a diagnostic agent in the follow up of patients with differentiated thyroid cancer: comparison with post I131 therapy whole body scanning. J Clin Endocrinol Metab. 2001;86:5294-5300.
5. Shankar LK, Yamamoto AJ, Alavi A, Mandel SJ. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med. 2002;43:72-76.
6. Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumour whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med. 2002;27:1-8.
7. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imag. 2003;30:1371-1377.
8. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648-654.